STING1 and COVID-19: Although lupus anticoagulant (found in roughly 20% of severe COVID-19) [52], and complement-mediated thrombotic microangiopathy might fuel some of those thrombosis, several evidence suggest that overactivation of the STING pathway also contributes to the hypercoagulability observed in COVID-19.